NEW YORK (GenomeWeb News) — Gene Logic has promoted Thomas Barnes to senior vice president of discovery, a position that will put him in charge of drug repositioning, the company said this week.
Barnes will take over the position from Louis Tartaglia, who is resigning from the job to become a partner in a venture capital firm.
Barnes formerly was co-founder of drug repositioning at Millennium Pharmaceuticals, which is now owned by Gene Logic.
Jonathan Rothberg has voluntarily and immediately resigned from his position as a member of CuraGen’s board of directors, the company said last week.
Oxford Genome Sciences has hired several new executives to its UK and US business branches, the company said this week.
Benjamin Reed, formerly of Ciphergen Biosystems, has been named the new business development director for the company’s UK biomarker services division.
David Bell, who was at GlaxoSmithKline for 18 years, has joined the company’s UK mass-spectrometry operations
The company has also named David Fitzpatrick and Beatrice Perotti to its pre-clinical group in San Francisco. Fitzpatrick, who previously worked at Immunex and at Amgen, will head the pre-clinical group and Perotti, who formerly worked at Pfizer and at Amgen, will lead preclinical development programs.
Per Artur Peterson has been appointed to Entelos’ board as a non-executive editor, the company said this week.
Peterson formerly was chairman of research and development and an executive committee member at Johnson & Johnson. Peterson also previously led the division of molecular immunogenetics at the Scripps Research Institute.
Transgenomic has named Frank Witney to its board of directors.
Witney is president, CEO and director of Panomics, and is a director of Applied Precision. He also has been president of PerkinElmer’s drug-discovery business and was COO of Packard Biosciences.
Enigma Diagnostics this week named Lynn Busteed to be its new CEO and director. .
Busteed was previously vice president for corporate development at Focus Diagnostics and was senior director of business development and strategic planning at Celera Genomics.
Anthony Altar has been named the new director of the National Institutes of Health’s Biomarker Consortium, a public-private partnership aimed at identifying and qualifying new biomarkers and developing them for therapeutic uses.
Altar has been president and CEO of Psychiatric Genomics, director of global neuroscience research at Otsuka America Pharmaceuticals, and was a research scientist at Regeneron Pharmaceuticals and at Genentech.
Raymond Arner and Anne Marie Cook will lead a new biotechnology-focused branch of the Michigan-based law firm Miller, Canfield, Paddock and Stone in Cambridge, Mass.
Arner was senior vice president and chief IP counsel at Biogen, and was vice president of global IP at Pharmacia. He also worked as an IP and patents counselor for Upjohn Company and DuPont Merck. .
Cook formerly was senior vice president of business development and corporate development, and general counsel and secretary of Viacell and was vice president and chief corporate counsel at Biogen Idec.
Anthony Fauci won the George M. Kober Medal of the Association of American Physicians this week.
Fauci has been director of the National Institutes of Allergy and Infectious Disease since 1984 and is known as a pioneer in immunoregulation, rheumatology, and HIV/AIDS.